Alterity Therapeutics Ltd

詳細情報 Alterity Therapeutics Ltd 企業名

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.

企業情報

企業コードATHE

会社名Alterity Therapeutics Ltd

上場日Mar 28, 2000

最高経営責任者「CEO」Dr. David A. Stamler, M.D.

従業員数10

証券種類Depository Receipt

決算期末Mar 28

本社所在地L 3 460 Bourke St

都市MELBOURNE

証券取引所NASDAQ Capital Market Consolidated

国Australia

郵便番号3000

電話番号61393494906

ウェブサイトhttps://alteritytherapeutics.com/

企業コードATHE

上場日Mar 28, 2000

最高経営責任者「CEO」Dr. David A. Stamler, M.D.

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Ms. Abby Macnish Niven

Chief Financial Officer, Company Secretary

--

Mr. Lawrence B. Gozlan

Non-Executive Director

--

Mr. Peter Ashley Marks

Non-Executive Independent Director

--

Mr. Brian Derek Meltzer

Non-Executive Independent Director

--

Ms. Hannah Howlett

Investor Relations

--

Mr. Geoffrey Paul Kempler

Non-Executive Chairman of the Board

--

Dr. David A. Stamler, M.D.

Chief Executive Officer

--

会社名

会社名/ポジション

ポジション

株式保有

変動額

Ms. Abby Macnish Niven

Chief Financial Officer, Company Secretary

--

Mr. Lawrence B. Gozlan

Non-Executive Director

--

Mr. Peter Ashley Marks

Non-Executive Independent Director

--

Mr. Brian Derek Meltzer

Non-Executive Independent Director

--

Ms. Hannah Howlett

Investor Relations

--

Mr. Geoffrey Paul Kempler

Non-Executive Chairman of the Board

--

収益内訳

データなし

データなし

事業別

地域別

データなし

株主

更新時刻: Sun, Jul 20

株主統計

種類

株主統計

比率

Point72 Asset Management, L.P.

0.86%

Morgan Stanley & Co. LLC

0.28%

Greenleaf Trust

0.11%

UBS Financial Services, Inc.

0.08%

BNP Paribas Securities Corp. North America

0.06%

Other

98.60%

株主統計

比率

Point72 Asset Management, L.P.

0.86%

Morgan Stanley & Co. LLC

0.28%

Greenleaf Trust

0.11%

UBS Financial Services, Inc.

0.08%

BNP Paribas Securities Corp. North America

0.06%

Other

98.60%

種類

株主統計

比率

Hedge Fund

0.86%

Research Firm

0.35%

Bank and Trust

0.11%

Investment Advisor

0.09%

Private Equity

0.04%

Other

98.56%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

25

222.41K

1.45%

+22.59K

2025Q1

25

242.89K

1.60%

+14.64K

2024Q4

25

125.35K

1.13%

-75.38K

2024Q3

25

113.89K

1.28%

-62.37K

2024Q2

24

79.19K

0.91%

-96.76K

2024Q1

24

95.17K

1.09%

-51.08K

2023Q4

23

88.25K

1.89%

-31.21K

2023Q3

26

59.08K

1.45%

-63.37K

2023Q2

27

58.44K

1.44%

-90.15K

2023Q1

26

93.79K

2.31%

-17.38K

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

Point72 Asset Management, L.P.

131.43K

0.86%

+98.80K

+302.83%

Mar 31, 2025

Morgan Stanley & Co. LLC

43.63K

0.29%

-700.00

-1.58%

Mar 31, 2025

UBS Financial Services, Inc.

13.00K

0.09%

+12.62K

+3286.46%

Mar 31, 2025

BNP Paribas Securities Corp. North America

9.75K

0.06%

+962.00

+10.94%

Mar 31, 2025

Twin Lakes Capital

5.92K

0.04%

--

Mar 31, 2025

Geode Capital Management, L.L.C.

1.16K

0.01%

--

May 31, 2025

Osaic Holdings, Inc.

181.00

0%

--

Mar 31, 2025

Rhumbline Advisers Ltd. Partnership

130.00

0%

+130.00

--

Mar 31, 2025

55IP

53.00

0%

+53.00

--

Mar 31, 2025

詳細を見る

5.225USD

Alterity Therapeutics Ltd

5.225

概要

企業名

金融